File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/j.1540-8167.2005.00299.x
- Scopus: eid_2-s2.0-33644869735
- PMID: 16403073
- WOS: WOS:000233807600021
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug
Title | Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug |
---|---|
Authors | |
Keywords | Ketoconazole QTc prolongation Torsades de pointes |
Issue Date | 2005 |
Publisher | Wiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1045-3873 |
Citation | Journal Of Cardiovascular Electrophysiology, 2005, v. 16 n. 12, p. 1375-1377 How to Cite? |
Abstract | Ketoconazole Induced Torsades de Pointes Ketoconazole is not known to be proarrhythmic without concomitant use of QT interval-prolonging drugs. We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection. Her QT interval returned to normal upon withdrawal of ketoconazole. Genetic study did not find any mutation in her genes that encode cardiac IKr channel proteins. We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome. |
Persistent Identifier | http://hdl.handle.net/10722/148455 |
ISSN | 2023 Impact Factor: 2.3 2023 SCImago Journal Rankings: 1.144 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mok, NS | en_US |
dc.contributor.author | Lo, YK | en_US |
dc.contributor.author | Tsui, PT | en_US |
dc.contributor.author | Lam, CW | en_US |
dc.date.accessioned | 2012-05-29T06:13:05Z | - |
dc.date.available | 2012-05-29T06:13:05Z | - |
dc.date.issued | 2005 | en_US |
dc.identifier.citation | Journal Of Cardiovascular Electrophysiology, 2005, v. 16 n. 12, p. 1375-1377 | en_US |
dc.identifier.issn | 1045-3873 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/148455 | - |
dc.description.abstract | Ketoconazole Induced Torsades de Pointes Ketoconazole is not known to be proarrhythmic without concomitant use of QT interval-prolonging drugs. We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection. Her QT interval returned to normal upon withdrawal of ketoconazole. Genetic study did not find any mutation in her genes that encode cardiac IKr channel proteins. We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome. | en_US |
dc.language | eng | en_US |
dc.publisher | Wiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1045-3873 | en_US |
dc.relation.ispartof | Journal of Cardiovascular Electrophysiology | en_US |
dc.subject | Ketoconazole | - |
dc.subject | QTc prolongation | - |
dc.subject | Torsades de pointes | - |
dc.subject.mesh | Antifungal Agents - Adverse Effects | en_US |
dc.subject.mesh | Coronary Artery Disease - Genetics - Physiopathology | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Ketoconazole - Adverse Effects | en_US |
dc.subject.mesh | Long Qt Syndrome - Chemically Induced | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Mutation | en_US |
dc.subject.mesh | Risk Factors | en_US |
dc.subject.mesh | Torsades De Pointes - Chemically Induced - Genetics | en_US |
dc.title | Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug | en_US |
dc.type | Article | en_US |
dc.identifier.email | Lam, CW:ching-wanlam@pathology.hku.hk | en_US |
dc.identifier.authority | Lam, CW=rp00260 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1111/j.1540-8167.2005.00299.x | en_US |
dc.identifier.pmid | 16403073 | - |
dc.identifier.scopus | eid_2-s2.0-33644869735 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-33644869735&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 16 | en_US |
dc.identifier.issue | 12 | en_US |
dc.identifier.spage | 1375 | en_US |
dc.identifier.epage | 1377 | en_US |
dc.identifier.isi | WOS:000233807600021 | - |
dc.publisher.place | United States | en_US |
dc.identifier.issnl | 1045-3873 | - |